OncoMatch/Clinical Trials/NCT05361174
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Is NCT05361174 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies IOV-4001 for unresectable melanoma.
Treatment: IOV-4001 — This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIC, IIID, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-PD-1 therapy
progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody
Must have received: anti-PD-L1 therapy
progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody
Must have received: BRAF inhibitor
received BRAF/MEK inhibitor in those with BRAF mutations
Must have received: MEK inhibitor
received BRAF/MEK inhibitor in those with BRAF mutations
Must have received: platinum-based chemotherapy
platinum doublet chemotherapy
Must have received: targeted therapy
progressed during/after ≥1 targeted therapy
Cannot have received: cell therapy involving prior conditioning chemotherapy
any form of cell therapy involving prior conditioning chemotherapy within the past 20 years
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
cardiac function test required
Participants who have adequate organ function. Cardiac function test required.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute · Los Angeles, California
- Sylvester Comprehensive Cancer Center · Miami, Florida
- Orlando Health Cancer Institute · Orlando, Florida
- Moffitt Cancer Center · Tampa, Florida
- The University of Kansas Cancer Center · Westwood, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05361174 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cell therapy involving prior conditioning chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIC or IIID or IV is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages